Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: Effects on cardiac hypertrophy and survival

Cardiovascular Research

Volumn 43, Issue 1, 1999, Pages 77-85

  Bastien, Natacha R ^a   Juneau, Anne Véronique ^a   Ouellette, Julie ^a   Lambert, Chantal ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

ACE inhibitors; AT1 receptors; Cardiomyopathy; Hypertrophy; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; QUINAPRIL; ALANINE AMINOTRANSFERASE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; CREATININE; ISOQUINOLINE DERIVATIVE; POTASSIUM; SODIUM; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; ENZYME INHIBITION; HAMSTER; HEART HYPERTROPHY; HEART MUSCLE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; DRUG ANTAGONISM; EVALUATION; MALE; PATHOLOGY; SYRIAN HAMSTER;

ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOMYOPATHY, DILATED; CREATININE; CRICETINAE; EVALUATION STUDIES; ISOQUINOLINES; LOSARTAN; MALE; MESOCRICETUS; MYOCARDIUM; POTASSIUM; RECEPTORS, ANGIOTENSIN; SODIUM; TETRAHYDROISOQUINOLINES;

EID: 0032589750     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00015-2     Document Type: Article

References (49)

1. Chemla D., Scalbert E., Desché P., Lecarpentier Y. La cardiomyopathie du hamster Syrien. Arch Mal Coeur. 84:1991;85-87.
2. Sakamoto A., Ono K., Abe M., et al. Both hypertrophic and dilated cardiomypathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA. 94:1997;13873-13878.
3. Hunter E.G., Hugues V., White J. Cardiomyopathic hamsters, CHF 146 and CHF 147: a preliminary study. Can J Physiol Pharmacol. 62:1984;1423-1428.
4. Haleen S.J., Weishaar R.E., Overhiser R.W., et al. Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster: Hemodynamic, morphological, and biochemical correlate. Circ Res. 68:1991;1302-1312.
5. Nakamura F., Nagano M., Kobayashi R., et al. Effects of an angiotensin-converting inhibitor, cilazapril, on congestive heart failure in cardiomyopathic hamsters. Nagano M., Takeda N., Dhalla N.S. The cardiomyopathic heart. 1994;145-156 Raven Press, New York.
6. Lambert C., Massillon Y., Meloche S. Renin-angiotensin system and the congenital cardiomyopathic hamsters. Singal P.K., Dixon I.M., Beamish R.E., Dhalla N.S. Mechanisms of heart failure. 1995;203-214 Kluwer Academic Publishers, Boston.
7. Shiota N., Fukamizu A., Takai S., Okunishi H., Murakami K., Miyazaki M. Activation of angiotensin II forming chymase in the cardiomyopathic hamster heart. J Hypertens. 15:1997;431-440.
8. Mansoor A.M., Honda M., Kuramochi T., Tanaka K., Morioka S., Takabatake T. Effects of ACE inhibition and beta-blockade on collagen remodeling in the heart of Bio 14.6 hamsters. Clin Exp Pharmacol Physiol. 23:1996;43-49.
9. Masutomo K., Makino N., Marymaya T., Shimada T., Yanaga T. Effects of enalapril on the collagen matrix in cardiomyopathic Syrian hamsters (Bio 14.6 and 53.58). Jpn Circ J. 60:1996;50-61.
10. Davison G., Hall C.S., Miller J.G., Scott M., Wickline S.A. Cellular mechanisms of captopril-induced matrix remodeling in Syrian hamsters cardiomyopathy. Circulation. 90:1994;1334-1342.
11. Hirakata H., Fouad-Tarazi F.M., Bumpus F.M., et al. Angiotensins and the failing heart. Enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril. Circ Res. 66:1990;891-899.
12. Narita H., Kaburaki M., Doi H., et al. Prolonging action of imidapril on the life expectancy of cardiomyopathic hamsters. J Cardiovasc Pharmacol. 27:1996;861-871.
13. Chemla D., Scalbert E., Desché P., Lerebours G., Suard I., Lecarpentier Y. Effects of early and late therapy with perindopril on survival and myocardial inotropic state in experimental dilated cardiomyopathy. J Cardiovasc Pharmacol. 24:1994;151-157.
14. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensin-aldosterone system. Circulation. 83:1991;1849-1865.
15. Milavetz J.J., Raya T.E., Johnson C.S., Morkin E., Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol. 27:1996;714-719.
16. Raya T.E., Fonkel S.J., Lee R.W., Daugherty S., Goldman S., Wong P.C., Timmermans P.B.M.W.M. Hemodynamic effects of direct angiotensin blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens. 4:1991;3345-3405.
17. Schieffer B., Wirger A., Meybrunn M., et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 89:1994;2273-2282.
18. Effects of enalapril on mortality in severe congestive heart failure. Result of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS. N Engl J Med. 316:1987;1429-1435.
19. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;678-689.
20. 1 receptors in congenital cardiomyopathic hamsters. Circ Res. 77:1995;1001-1007.
21. Wong P.C., Tam S.W., Herblin W.F., Timmermans P.B. Further studies on the selectivity of DuP 753, nonpeptide angiotensin II receptor antagonists. Eur J Pharmacol. 196:1991;201-203.
22. De Léan A., Munson P.J., Rodbard D.D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 235:1978;E97-E102.
23. Wikman-Coffelt J., Sievers R., Parmley W.W., Jasmin G. Verapamil preserves adenine nucleotide pool in cardiomyopathic Syrian hamsters. Am J Physiol. 250:1986;H22-H28.
24. Lanza G.M., Scott M.J., Davison G., et al. Angiotensin II receptor blockade in Syrian hamsters (T0-2) cardiomyopathy does not affect microscopic cardiac material properties: implications for mechanisms of tissue remodeling. Cardiovasc Drugs Ther. 11:1997;521-529.
25. Mitchell S.F., Marks E.S., Patterson R.E., Speir E.H., Steadman K.A., Keiser H.R. Correlation of changes in cardiac calcium channels with hemodynamics in Syrian hamster cardiomyopathy and heart failure. Life Sci. 41:1987;153-159.
26. Nishimiki T., Yamagishi H., Takeuchi K., Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in hypertensive rat. Cardiovasc Res. 29:1995;856-861.
27. Mulder P., Devaux B., Richard V., et al. Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure: effects on survival, hemodynamics, and cardiovascular remodeling. Circulation. 95:1997;1314-1319.
28. Pfeffer M.A., Pfeffer J.M., Steinberg C., Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circ Res. 72:1985;406-412.
29. Gravas H., Gravas I. Cardioprotective potential of angiotensin-converting enzyme inhibitors. J Hypertens. 9:1991;385-392.
30. Bao G., Gohlke P., Qadri F., Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension. 20:1992;74-79.
31. Linz W., Scholkens B.A. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 105:1992;771-772.
32. Mc Donald K., Mock J., D'Aloia A., et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 91:1995;2043-2048.
33. Liu Y.H., Yang X.P., Sharov V.G., et al. Effects of angiotensin-converting enzyme inhibitors angiotensin II type 1 receptor antagonists with heart failure. J Clin Invest. 99:1997;1926-1935.
34. 2 mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 95:1995;651-657.
35. 1: gain-of-function study using gene transfer. Proc Natl Acad Sci USA. 92:1995;10663-10667.
36. Booz G.W., Baker K.M. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension. 28:1996;635-640.
37. 1 receptor-mediated pressor and chronotropic effects. J Clin Invest. 101:1998;527-535.
38. 2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 267:1994;H844-H852.
39. Nio Y., Matsubara H., Murasawa S., Kanasaki M., Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 95:1995;46-54.
40. 1-receptor subtype in failing human ventricular myocardium. Circulation. 95:1997;1193-1200.
41. Nosawa Y., Mikaye H., Haruno A., et al. Down-regulation of angiotensin II receptors in hypertrophied human myocardium. Clin Exp Pharmacol Physiol. 23:1996;514-518.
42. Dostal D.E., Baker K.M. Evidence of a role of an intracardiac renin-angiotensin system in normal and failing hearts. Trends Cardiovasc Med. 3:1993;67-74.
43. Lambert C., Godin D., Fortier P., Nadeau R. Direct effects in vivo of angiotensins I and II on the canine sinus node. Can J Physiol Pharmacol. 69:1991;389-392.
44. Lindpainter K., Lu W., Niedermayer N., et al. Selective activation of cardiac angiotensinogen gene expression on post-infarction ventricular remodeling in the rat. J Mol Cell Cardiol. 25:1993;133-143.
45. Schomisch-Moravec C., Schluchter M.D., Paranandi L., et al. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation. 82:1990;1973-1984.
46. 2+ responsiveness? J Pharmacol Toxicol Methods. 37:1997;205-214.
47. Holubarsch C., Hasenfuss G., Schmidt-Schweda S., Knorr A., Pieske B., Ruf T., Fasol R., Just H. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions. Circulation. 88:1993;1228-1237.
48. Scott A., Chang R.S.L., Lotti V.J., Siegl P.K.S. Cardiac angiotensin receptors: effects of selective angiotensin II receptor antagonists, DUP 753 and PD 121981, in rabbit heart. J Pharmacol Exp Ther. 261:1992;931-935.
49. Ishihata A., Endoh M. Pharmacological characteristics of the positive chronotropic effect of angiotensin II in the rabbit ventricular myocardium. Br J Pharmacol. 108:1993;999-1005.